Abstract Number: 1108 • 2019 ACR/ARP Annual Meeting
Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS)
Background/Purpose: Mobile applications promise to facilitate the life of patients as well as physicians. In routine practice, however, rheumatology apps are largely unknown and little…Abstract Number: 1109 • 2019 ACR/ARP Annual Meeting
Development of Smart-phone Spondyloarthritis Management System and Real-world Study of Chinese Patients with Ankylosing Spondylitis
Background/Purpose: We developed a multipurpose digital platform, Smart-phone SpondyloArthritis Management System (SpAMS), based on two of the most important objectives: 1) for patients: to activate…Abstract Number: 1110 • 2019 ACR/ARP Annual Meeting
Expanding Access to Research Using Tele-Health: Lupus and Informatics Feasibility Study
Background/Purpose: Participating in clinical research can be burdensome for subjects due to time and travel barriers, particularly among underserved, rural, and/or chronic disease bearing populations…Abstract Number: 1111 • 2019 ACR/ARP Annual Meeting
Lupus Teledematology: A Pilot Project to Evaluate the Plausibility of a Rapid Access Dermatology Service for Lupus Patients
Background/Purpose: Clinicians have been increasingly using social media sites professionally. Platforms such as WhatsApp ® could be a potentially effective tool in teledermatology for rapid diagnosis and/or…Abstract Number: 1112 • 2019 ACR/ARP Annual Meeting
Rheumatologists’ Opinions and Use of Telemedicine in the Southwestern U.S
Background/Purpose: Telemedicine (TM) is increasingly employed in chronic disease management and can reduce barriers in access to care. In the Southwestern U.S., where there is…Abstract Number: 1113 • 2019 ACR/ARP Annual Meeting
Improving Healthcare Quality and Reducing Cost via Online Interaction for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tool
Background/Purpose: Without efficient primary medical care and follow-up system in China, patients can choose any hospital or doctor they like in seeking medical care. As…Abstract Number: 1114 • 2019 ACR/ARP Annual Meeting
Survival and Cost of Biologic DMARDs in a Military Medical Center: A Quality Improvement Initiative
Background/Purpose: High drug costs and lack of transparency of these costs is a major concern in the United States. Biologic therapy for rheumatoid arthritis (RA)…Abstract Number: 1115 • 2019 ACR/ARP Annual Meeting
Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)
Background/Purpose: Chronic inflammatory diseases (CIDs) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis (PsO), ankylosing spondylitis (AS), Crohn's disease (CD), and ulcerative colitis…Abstract Number: 1116 • 2019 ACR/ARP Annual Meeting
Non-medical Switching from Reference to Biosimilar Etanercept – No Evidence for Nocebo Effect – a Retrospective Analysis of Real-life Data
Background/Purpose: Real-world data about switching patients from originator product to a biosimilars are important to assess and to document the outcome of switches in clinical…Abstract Number: 1117 • 2019 ACR/ARP Annual Meeting
Government Subsidization of Biologic Therapy for Inflammatory Arthritis in a Co-Funded Healthcare Model: A Singapore Experience
Background/Purpose: Real world utilization of biologic therapy for inflammatory arthritis often falls short of international best practice and is heavily influenced by affordability and national…Abstract Number: 1118 • 2019 ACR/ARP Annual Meeting
US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation
Background/Purpose: To expand treatment options, increase access to life-saving medications, and lower healthcare costs through competition, the US Congress created an abbreviated licensure pathway for…Abstract Number: 1119 • 2019 ACR/ARP Annual Meeting
Patterns of Medication Use for Patients with Sarcoidosis: Data from the ACR’s RISE Registry
Background/Purpose: Sarcoidosis results in significant morbidity and mortality but is a generally understudied disease. There are currently no FDA approved drugs for the treatment of…Abstract Number: 1120 • 2019 ACR/ARP Annual Meeting
Prevalence of Burnout in Rheumatology Professionals
Background/Purpose: Burnout among physicians has major implications for health care. We measured prevalence of burnout in a large group of Rheumatology professionals attending a national…Abstract Number: 1121 • 2019 ACR/ARP Annual Meeting
The Association Between Physician Sex and Faculty Rank Among Academic Rheumatologists in the United States
Background/Purpose: In contrast to historical trends, women now comprise more than half of rheumatology fellowship graduates in the United States (US). Differences in academic rank…Abstract Number: 1122 • 2019 ACR/ARP Annual Meeting
Factors Impacting Referral of Juvenile Idiopathic Arthritis Patients to a Tertiary Level Pediatric Rheumatology Center in North India
Background/Purpose: JIA studies demonstrate that there is a “window of opportunity” early in the disease course during which appropriate management improves outcomes: prompt referral to…
ACR Meeting Abstracts